CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

被引：9

作者：

Choueiri, T. K. ^{[1
]}

Halabi, S. ^{[2
]}

Sanford, B. ^{[2
]}

Hahn, O. ^{[3
]}

Michaelson, M. D. ^{[4
]}

Walsh, M. ^{[1
]}

Olencki, T. ^{[5
]}

Picus, J. ^{[6
]}

Small, E. J. ^{[7
]}

Dakhil, S. ^{[8
]}

George, D. ^{[9
]}

Morris, M. J. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA

[2] Duke Univ, Biostat & Bioinformat, Durham, NC USA

[3] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA

[4] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA

[5] Ohio State Univ, Med Ctr, Med Oncol, Columbus, OH 43210 USA

[6] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA

[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Med Oncol, San Francisco, CA USA

[8] Canc Ctr Kansas, Hematol, Wichita, KS USA

[9] Duke Univ, Med Oncol, Durham, NC USA

[10] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1093/annonc/mdw435.23

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

LBA30_PR

引用

页数：1